Category: Covid-19 Vaccine

Page 483«..1020..482483484485..490500..»

Philippines receives COVID-19 vaccine after delays – ABC News

February 28, 2021

The Philippines has received its first batch of COVID-19 vaccine

By JIM GOMEZ Associated Press

February 28, 2021, 9:23 AM

3 min read

MANILA, Philippines -- The Philippines received its first batch of COVID-19 vaccine Sunday, among the last in Southeast Asia to secure the critical doses despite having the second-highest number of coronavirus infections and deaths in the hard-hit region.

A Chinese military transport aircraft carrying 600,000 doses of vaccine donated by China arrived in an air base in the capital in a late-afternoon event beamed live on state-run TV. President Rodrigo Duterte and top Cabinet officials welcomed the delivery of the vaccine from China-based Sinovac Biotech Ltd. in a televised ceremony that underscored their relief after weeks of delays, officials said.

That plane is carrying hope that we can finally return to our lives and light for our very dark journey, presidential spokesperson Harry Roque said.

Vaccinations initially of health workers and top officials led by the health secretary were scheduled to start in six Metropolitan Manila hospitals Monday.

Aside from the donated vaccine from Sinovac Biotech, the government has separately ordered 25 million doses from the China-based company. An initial 525,600 doses of COVID-19 vaccine from AstraZeneca were also scheduled to arrive Monday, Roque said.

The initial deliveries are a small fraction of at least 148 million doses the government has been negotiating to secure from Western and Asian companies to vaccinate about 70 million Filipinos for free in a massive campaign largely funded with foreign and domestic loans. The bulk of the vaccine shipments are expected to arrive later this year.

Resty Padilla, a spokesperson for a government panel dealing with the pandemic, said the vaccine could be a game-changer in a debilitating health crisis that has infected more than 576,000 people in the Philippines and killed at least 12,318 others. Lockdowns and quarantine restrictions have also set back Manilas economy in one of the worst recessions in the region and sparked unemployment and hunger.

Although we are still a long way from herd immunity, the arrival of the initial supply of vaccine provides hope that our road to normalcy has finally begun, Padilla told The Associated Press.

Dutertes administration has come under criticism for lagging behind most other Southeast Asian countries in securing the vaccines, including much smaller and poorer ones like Cambodia, Myanmar and Laos.

The tough-talking Duterte has said wealthy Western countries, especially where the vaccine originated, have cornered massive doses for their citizens, leaving poorer nations scrambling to get the rest. In a sign of desperation, the president said last December that he would proceed to abrogate a key security pact with the United States that allows large numbers of American troops to conduct war exercises in the Philippines if Washington could not provide at least 20 million doses of COVID-19 vaccine for his country.

No vaccine, no stay here, Duterte said then.

The Chinese vaccine delivery was delayed due to the absence of an emergency-use authorization from Manilas Food and Drug Administration. Sinovac got the authorization last Monday. Western pharmaceutical companies also wanted the Philippine government to guarantee that it would take responsibility for lawsuits and demands for indemnity arising from possible adverse side effects from the vaccine, officials said.

Duterte signed a law last week giving pharmaceutical companies immunity from such liabilities for the emergency use by the public of their vaccine.

Associated Press writer Edna Tarigan in Jakarta, Indonesia, contributed to this report.

Go here to read the rest:

Philippines receives COVID-19 vaccine after delays - ABC News

Pflugerville ISD will pay employees to get COVID-19 vaccine – KXAN.com

February 28, 2021

`;// articleContent = document.querySelector(".article-content");// articleContent.innerHTML = articleContent.innerHTML + formbox;let firstParagraph = document.querySelector("div.article-content > p:nth-child(1)");if (firstParagraph !== null) {firstParagraph.insertAdjacentHTML("afterend", formbox);}function waitForElement(id, callback){var goStahp = setInterval(function(){if(document.getElementById(id)){clearInterval(goStahp);callback();}}, 100);}waitForElement("JotFormIFrame-202185815209151", function(){const expandButton = document.querySelector('h3.expand_box_click_to_open_covid_form');expandButton.addEventListener('click', function() {let box = document.querySelector('.corona_form_expand_box_covid_form');let first = 'opening';let second = 'open';let buttonAction = 'Hide story tip submission form';let deviceAction = "Tap";if (window.innerWidth > 666) {deviceAction = "Click";}// console.log(window.innerWidth);if(box.classList.contains(first)) {[first, second] = [second, first];buttonAction = `${deviceAction} to submit a coronavirus story tip`;}expandButton.innerHTML = buttonAction;box.classList.toggle(first);setTimeout(() => {box.classList.toggle(second);}, 0);});var ifr = document.getElementById("JotFormIFrame-202185815209151");if(window.location.href && window.location.href.indexOf("?") > -1) {var get = window.location.href.substr(window.location.href.indexOf("?") + 1);if(ifr && get.length > 0) {var src = ifr.src;src = src.indexOf("?") > -1 ? src + "&" + get : src + "?" + get;ifr.src = src;}}window.handleIFrameMessage = function(e) {if (typeof e.data === 'object') { return; }var args = e.data.split(":");if (args.length > 2) { iframe = document.getElementById("JotFormIFrame-" + args[(args.length - 1)]); } else { iframe = document.getElementById("JotFormIFrame"); }if (!iframe) { return; }switch (args[0]) {case "scrollIntoView":iframe.scrollIntoView();break;case "setHeight":console.log(`case: setHeight`);iframe.style.height = parseInt(args[1]) + 15 + "px";break;case "collapseErrorPage":console.log(`case: collapseErrorPage`);if (iframe.clientHeight > window.innerHeight) {iframe.style.height = window.innerHeight + "px";}break;case "reloadPage":window.location.reload();break;case "loadScript":var src = args[1];if (args.length > 3) {src = args[1] + ':' + args[2];}var script = document.createElement('script');script.src = src;script.type = 'text/javascript';document.body.appendChild(script);break;case "exitFullscreen":if (window.document.exitFullscreen) window.document.exitFullscreen();else if (window.document.mozCancelFullScreen) window.document.mozCancelFullScreen();else if (window.document.mozCancelFullscreen) window.document.mozCancelFullScreen();else if (window.document.webkitExitFullscreen) window.document.webkitExitFullscreen();else if (window.document.msExitFullscreen) window.document.msExitFullscreen();break;}var isJotForm = (e.origin.indexOf("jotform") > -1) ? true : false;if(isJotForm && "contentWindow" in iframe && "postMessage" in iframe.contentWindow) {var urls = {"docurl":encodeURIComponent(document.URL),"referrer":encodeURIComponent(document.referrer)};iframe.contentWindow.postMessage(JSON.stringify({"type":"urls","value":urls}), "*");}};if (window.addEventListener) {window.addEventListener("message", handleIFrameMessage, false);} else if (window.attachEvent) {window.attachEvent("onmessage", handleIFrameMessage);}});//

Read the original here:

Pflugerville ISD will pay employees to get COVID-19 vaccine - KXAN.com

Austins Circuit of the Americas officially opens as mass COVID-19 vaccination hub – KXAN.com

February 28, 2021

`;// articleContent = document.querySelector(".article-content");// articleContent.innerHTML = articleContent.innerHTML + formbox;let firstParagraph = document.querySelector("div.article-content > p:nth-child(1)");if (firstParagraph !== null) {firstParagraph.insertAdjacentHTML("afterend", formbox);}function waitForElement(id, callback){var goStahp = setInterval(function(){if(document.getElementById(id)){clearInterval(goStahp);callback();}}, 100);}waitForElement("JotFormIFrame-202185815209151", function(){const expandButton = document.querySelector('h3.expand_box_click_to_open_covid_form');expandButton.addEventListener('click', function() {let box = document.querySelector('.corona_form_expand_box_covid_form');let first = 'opening';let second = 'open';let buttonAction = 'Hide story tip submission form';let deviceAction = "Tap";if (window.innerWidth > 666) {deviceAction = "Click";}// console.log(window.innerWidth);if(box.classList.contains(first)) {[first, second] = [second, first];buttonAction = `${deviceAction} to submit a coronavirus story tip`;}expandButton.innerHTML = buttonAction;box.classList.toggle(first);setTimeout(() => {box.classList.toggle(second);}, 0);});var ifr = document.getElementById("JotFormIFrame-202185815209151");if(window.location.href && window.location.href.indexOf("?") > -1) {var get = window.location.href.substr(window.location.href.indexOf("?") + 1);if(ifr && get.length > 0) {var src = ifr.src;src = src.indexOf("?") > -1 ? src + "&" + get : src + "?" + get;ifr.src = src;}}window.handleIFrameMessage = function(e) {if (typeof e.data === 'object') { return; }var args = e.data.split(":");if (args.length > 2) { iframe = document.getElementById("JotFormIFrame-" + args[(args.length - 1)]); } else { iframe = document.getElementById("JotFormIFrame"); }if (!iframe) { return; }switch (args[0]) {case "scrollIntoView":iframe.scrollIntoView();break;case "setHeight":console.log(`case: setHeight`);iframe.style.height = parseInt(args[1]) + 15 + "px";break;case "collapseErrorPage":console.log(`case: collapseErrorPage`);if (iframe.clientHeight > window.innerHeight) {iframe.style.height = window.innerHeight + "px";}break;case "reloadPage":window.location.reload();break;case "loadScript":var src = args[1];if (args.length > 3) {src = args[1] + ':' + args[2];}var script = document.createElement('script');script.src = src;script.type = 'text/javascript';document.body.appendChild(script);break;case "exitFullscreen":if (window.document.exitFullscreen) window.document.exitFullscreen();else if (window.document.mozCancelFullScreen) window.document.mozCancelFullScreen();else if (window.document.mozCancelFullscreen) window.document.mozCancelFullScreen();else if (window.document.webkitExitFullscreen) window.document.webkitExitFullscreen();else if (window.document.msExitFullscreen) window.document.msExitFullscreen();break;}var isJotForm = (e.origin.indexOf("jotform") > -1) ? true : false;if(isJotForm && "contentWindow" in iframe && "postMessage" in iframe.contentWindow) {var urls = {"docurl":encodeURIComponent(document.URL),"referrer":encodeURIComponent(document.referrer)};iframe.contentWindow.postMessage(JSON.stringify({"type":"urls","value":urls}), "*");}};if (window.addEventListener) {window.addEventListener("message", handleIFrameMessage, false);} else if (window.attachEvent) {window.attachEvent("onmessage", handleIFrameMessage);}});//

Read the original post:

Austins Circuit of the Americas officially opens as mass COVID-19 vaccination hub - KXAN.com

When will kids get the COVID-19 vaccine? – KARE11.com

February 28, 2021

Only one vaccine has approval for kids 16 and older. There's still a lot of data that needs to be collected.

ST PAUL, Minn. Governor Tim Walz released an updated timeline on Thursday showing when various groups may have access to COVID-19 vaccines, but theres still a big question lingering:

When will kids get their shots?

Only one vaccine, from Pfizer, has received FDA approval for any type of minor and even that product can only be given to children 16 and older. Walzs timeline places people age 16 years and over with any underlying medical condition in the late spring category, but it is difficult for experts to predict when all kids will gain widespread access.

Dr. Jill Foster, the Division Director for Pediatric Infectious Diseases at the U of M, said its an interesting question without firm answers right now.

For kids under 16, we dont have an approved vaccine. That has taken a little while, and I think people want it to take a little while, Foster said. Because we want to make sure we get it right.

Last week, Dr. Anthony Fauci predicted that high school students could be vaccinated in the fall, although for younger grades, it may not happen until early 2022. Due to the lack of data, the exact timing remains uncertain.

Pfizer and Moderna, however, are both studying the impact of the vaccine on kids 12 and older and have said theyd like to share some data by the spring.

At the U of M, Dr. Foster said Faucis timeline of vaccinations during the 2021-2022 school year seems feasible.

I think for the older teens, theyre probably going to be able to get the same vaccine as the adults, Foster said, so its just a matter for them of having enough vaccine supply.

But it may not be so simple for the younger age groups. Foster pointed out that its common for vaccines to impact children and adults different, hence the potential need for some slight adjustments.

Pediatricians like to say that kids are not just little adults. Sometimes, they are going to react differently, Foster said. Kids immune systems are different. Theyve had shorter time to be exposed to various pathogens and other vaccines. Its a little bit tricky.

See the article here:

When will kids get the COVID-19 vaccine? - KARE11.com

No walk-ins: Virginia Beach church advises COVID-19 vaccine registration is full ahead of weekend event – WAVY.com

February 28, 2021

VIRGINIA BEACH, Va. (WAVY) -- Virginia Beach Police say a North Carolina man was arrested Friday in connection with a shooting earlier this week that left two women with injuries.

Jeffrey Nigel Carr,26, of Moyock, was arrested and charged with two counts of malicious wounding, three counts of Shooting into an occupied dwelling, two counts of use of firearm in commission of a felony, and three counts of destruction of property.

More:

No walk-ins: Virginia Beach church advises COVID-19 vaccine registration is full ahead of weekend event - WAVY.com

Select boards push for increased focus on local COVID-19 vaccination sites – GazetteNET

February 28, 2021

Published: 2/27/2021 6:30:33 PM

Deerfield, Whately and Sunderland have all signed a letter to Gov. Charlie Baker opposing the prioritization of mass COVID-19 vaccination sites over local vaccination sites.

We just have to try to get more vaccines more vaccines to come into Franklin County, said Deerfield Board of Health Chairwoman Carolyn Shores Ness at the Franklin Regional Council of Governments (FRCOG) vaccine clinic at Tree House Brewing on Thursday, where 500 doses were scheduled to be administered over two days. We certainly have the capacity to do much more, and were hoping the governor will see this.

All three select boards discussed and signed the letter this week, which argued that local governments are intimately familiar with their communities.

We know who our most vulnerable and hard-to-reach populations are and have plans in place to work with them, the letter states. The mass vaccination sites fail to account for those high-risk individuals in need, especially in rural communities that lack adequate public transportation options.

At a Sunderland Select Board meeting earlier this week, board member Tom Fydenkevez said Baker fails to understand the importance of individual communities.

We dont really have any mass transit; we cant get from Point A to Point B easily, he said. Having mass vaccination sites in Springfield and Gillette Stadium and Fenway Park they may be able to push numbers, but youre not going to actually gain inroads into our population that needs the service.

Whately Select Board member Jonathan Edwards said at a board meeting Wednesday night that while there are many people who believe mass vaccination sites are more effective, they present barriers to a large segment of the population.

The challenge of mass sites is they are a huge barrier to people without online capabilities for signing up, Edwards said. It means theyre in large places that potentially are not convenient to more rural places.

We really do know what were doing, he said.

Whately Town Administrator Brian Domina said the states emphasis on mass vaccination sites means more vaccines are sent to larger, more urban communities in western Massachusetts, as opposed to locally run clinics, such as the one held at Tree House Brewing.

What the state is saying is Were going to give 500 (vaccines) to Eastfield Mall in Springfield, because its a regional site, because its western Mass., so everybody can get to Springfield, he said. Thats the stance the state is taking.

The distance to a vaccine site is enough to deter people from getting the vaccine, Domina added.

Convenience (of getting a) vaccine is one reason to get the vaccine, Edwards said. We dont want to put up obstacles to get the vaccine, we want to remove obstacles to get the vaccine.

Here is the original post:

Select boards push for increased focus on local COVID-19 vaccination sites - GazetteNET

Illinois COVID-19 vaccine eligibility expands to people with health conditions – Chicago Tribune

February 28, 2021

People ages 16 to 64 with the following conditions may be eligible for vaccines Thursday: cancer, chronic kidney disease, pulmonary diseases, smoking, diabetes, heart conditions, solid organ transplant, obesity, pregnancy, sickle cell disease and disabilities. There are an estimated 3.2 million people in Illinois in that group.

View post:

Illinois COVID-19 vaccine eligibility expands to people with health conditions - Chicago Tribune

These maps help show how the COVID-19 vaccine rollout is going in every U.S. state – East Bay Times

February 28, 2021

The Path to Immunity

Historical trends show there are different challenges to getting shots in arms, depending on where people live.

On Feb. 24, Surgo Ventures unveiled a data tool: The U.S. COVID-19 Vaccine Coverage Index to track major barriers in getting people vaccinated.

The index was created to assist federal, state and county decisionmakers in identifying which communities face challenges to vaccine coverage and why, based on the community-level barriers affecting COVID-19 vaccine uptake.

The index captures 28 supply and demand factors through five different themes. Surgos news release said the indexs modular design helps contextualize vaccine rollout performance and highlight inequities across communities helping keep a pulse on the pace of efforts to ensure equitable, efficient vaccination.

This map shows counties with the highest and lowest levels of concern of distributing the vaccine to its population, according to the index.

Click on the map to go to the site and see how each county compares.

The five themes that make up the index are:

According to the index, the following states are the highest concern when it comes to ensuring widespread vaccine coverage:

These maps show several challenges in each state:

Heres how the rollout is going in each state, according to the index:

U.S. rates

In the U.S., the latest vaccination rate is 1,275,497 doses per day, on average. At this rate, it will take an estimated nine months to cover 75% of the population with a two-dose vaccine.

Across the U.S.

As of Feb. 24, 44.5 million people have received at least one dose. At least 19.9 million people have completed the two-dose vaccination regimen.

And, 19.6 doses have been administered for every 100 people, and 79% of the shots delivered to states have been administered.

According to Bloomberg, the first stage of the U.S. rollout fell short of federal projections as vaccinations proceeded unevenly across the states. After focusing first on hospitals and other institutional health-care settings, the next phase of vaccinations will draw more on pharmacies and health clinics.

California has the highest daily rate of doses given at 209,334. Florida has the second-highest rate at 115,287.

You can visit the Bloomberg site for daily updates on vaccination progress.

The rest is here:

These maps help show how the COVID-19 vaccine rollout is going in every U.S. state - East Bay Times

COVID-19 Vaccines May Need Updates For Viral Variants : Shots – Health News – NPR

February 26, 2021

Vaccine makers are moving to test booster shots, prompted by new coronavirus variants that have sprung up in South Africa, the U.K. and elsewhere. Mark Felix/AFP via Getty Images hide caption

Vaccine makers are moving to test booster shots, prompted by new coronavirus variants that have sprung up in South Africa, the U.K. and elsewhere.

The U.S. is still ramping up its vaccination program, hoping to finally clamp down on the COVID-19 pandemic. But even as vaccine doses are being rolled out, their makers are exploring several strategies to bolster them, hoping to protect people against worrying new variants that have sprung up in recent months, from South Africa to the U.K.

The companies that have FDA-authorized vaccines are currently working on the problem, out of concern that mutations in SARS-CoV-2 could make the virus more difficult to control. Several strains seem to spread more easily than older forms of the coronavirus. There are also concerns that some mutated versions could elude antibody responses that would normally protect people who have been immunized or previously infected.

Here's an overview of the approaches being pursued by Pfizer and its partner BioNTech and Moderna the drugmakers with U.S.-authorized vaccines along with Johnson & Johnson, whose vaccine is now poised for FDA authorization:

Booster shots of the existing vaccine: This approach relies on giving people who have already been vaccinated a follow-up dose of the same vaccine.

Pfizer and BioNTech calls for people who have already completed the normal two-dose regimen to get a third 30-microgram dose, 6-12 months later. Moderna's plan calls for a 50-microgram dose, after people have gone through its two-dose regimen.

Variant-specific booster shot: Much like how specific vaccines are tailored to fight influenza, drugmakers can craft a version of their vaccine to combat individual coronavirus variants. Moderna says its new vaccine candidate, based on the strain first identified in South Africa, is now ready for clinical testing. The company says it has shipped doses of that potential vaccine to the National Institutes of Health to get started.

Last month, Paul Stoffels, the chief scientific officer at Johnson & Johnson, said his company is also preparing a special version of its vaccine to target the spike protein found in the B.1.351 seen in South Africa.

A 'multivalent' booster: In this approach, drug companies essentially blend two versions of their vaccines into a single booster shot. One would target original or "ancestral" versions of SARS-CoV-2, while the other would go after new variants. Moderna says it will look at combining its original vaccine known as mRNA-1273 with the newer version it created to fight the B.1.351 coronavirus variant first identified in South Africa.

Putting the boosters front-and-center: As drugmakers tweak their original vaccines to respond more acutely to variants, they will also consider whether new versions of their vaccines might effectively replace the initial recipes. Moderna says it will explore whether its variant-specific booster and its multivalent booster should become the primary vaccination series of shots for people who haven't been exposed to the coronavirus.

In the future, different circumstances will likely determine which vaccine or booster a person receives.

Someone who has antibodies from a previous infection or immunization would probably only get a booster shot, for instance, while someone whose system hasn't been exposed to the coronavirus would receive "an updated vaccine that aims to provide immunity to both the ancestral strains and variants of concern," Moderna said on Thursday, during a call with investors.

It's also possible people could receive a vaccine that's tailored to variants that have been detected in their country.

Johnson & Johnson's new vaccine was found to be 66% effective at preventing moderate to severe cases of COVID-19 a result that reflects testing in numerous countries, including South Africa and Brazil, where troubling new variants have emerged.

Current versions of their vaccines work against the new COVID-19 strains, Pfizer, Moderna and Johnson & Johnson say. Health experts also stress that all three of the vaccines are overwhelmingly effective in preventing the worst outcomes, such as hospitalizations and deaths. Still, newly tailored versions of the vaccines may be needed, as strains of SARS-CoV-2 continue to mutate and combine.

"While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine, we are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine," Pfizer CEO and Chairman Albert Bourla said in a statement about his company's plans to study boosters' effect on variants.

Pharmaceutical companies are studying boosters out of caution, Bourla added, to make sure they have an answer in the pipeline for an evolving coronavirus and to ensure they have a path for emergency authorization if an updated vaccine or booster becomes necessary.

"This regulatory pathway is already established for other infectious diseases like influenza," said Ugur Sahin, CEO and co-founder of BioNTech.

Both Moderna and Pfizer/BioNTech created their vaccines using relatively new messenger RNA technology, which has been hailed for its ability to produce vaccine candidates quickly. That swift process, the drug makers say, can also help them produce new versions of their vaccines in response to coronavirus mutations.

Citing the speed and flexibility of mRNA, Moderna CEO Stphane Bancel said on Thursday that his company "is committed to making as many updates to our vaccine as necessary until the pandemic is under control."

In contrast, Johnson & Johnson used a viral vector technique to make its vaccine, using the same strategy as the AstraZeneca / University of Oxford team. The approach is known to take longer than mRNA, but the resulting vaccine can also give patients immunity after a single dose.

Along with providing protection against new coronavirus variants, another potential benefit of booster shots, drug makers say, is that they can prolong or enhance protection even at smaller doses than the original regimen, easing some of the pressure on strained production and distribution networks.

Go here to see the original:

COVID-19 Vaccines May Need Updates For Viral Variants : Shots - Health News - NPR

Page 483«..1020..482483484485..490500..»